New hope for lupus nephritis: experimental drug VIB4920 enters Mid-Stage trial

NCT ID NCT05201469

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called VIB4920 in people with active lupus nephritis, a serious kidney complication of lupus. About 74 adults will receive either VIB4920 or a placebo, along with standard medications, to see if the drug helps improve kidney function. The goal is to find a better way to control the disease and reduce kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VIB4920 (an experimental drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for lupus nephritis, potentially helping more people achieve kidney remission.
What could go wrong: This is an early phase 2 trial with only 74 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Locations

Columbia University Medical Center: Department of Medicine, Division of Rheumatology
RECRUITING

New York, New York, 10032, United States
Emory University School of Medicine: Division of Rheumatology
RECRUITING

Atlanta, Georgia, 30307, United States
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases
RECRUITING

Manhasset, New York, 11030, United States
Hospital for Special Surgery, New York: Division of Rheumatology
NOT_YET_RECRUITING

New York, New York, 10021, United States
Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology
RECRUITING

Hershey, Pennsylvania, 17033, United States
Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology
RECRUITING

Philadelphia, Pennsylvania, 19140, United States
UCLA Medical Center: Division of Rheumatology
RECRUITING

Los Angeles, California, 90095, United States
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology
RECRUITING

La Jolla, California, 92093, United States
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center
RECRUITING

San Francisco, California, 94143, United States
University of Chicago, Department of Medicine: Rheumatology
RECRUITING

Chicago, Illinois, 60637, United States
University of Colorado School of Medicine: Division of Rheumatology
RECRUITING

Aurora, Colorado, 80045, United States
University of Miami Miller School of Medicine: Nephrology & Hypertension Division
RECRUITING

Miami, Florida, 33136, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
Washington University School of Medicine in St. Louis: Division of Nephrology
RECRUITING

St Louis, Missouri, 63110, United States
Yale University School of Medicine: Section of Rheumatology
RECRUITING

New Haven, Connecticut, 06519, United States
of California, Irvine School of Medicine Division of Rheumatology
RECRUITING

Orange, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.